Curium agreed to buy Lantheus in a deal valued at up to $8 billion, combining Curium’s global manufacturing and theranostics platform with Lantheus’ U.S. radiodiagnostics footprint. Curium will pay $102.50 per Lantheus share in cash at closing, with contingent value rights (CVRs) tied to sales milestones that could add up to $12 more per share through 2030.